-$1.28 Earnings Per Share Expected for bluebird bio, Inc. (NASDAQ:BLUE) This Quarter

Analysts expect bluebird bio, Inc. (NASDAQ:BLUEGet Rating) to post earnings per share (EPS) of ($1.28) for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for bluebird bio’s earnings, with estimates ranging from ($1.68) to ($0.93). bluebird bio reported earnings per share of ($3.58) during the same quarter last year, which would indicate a positive year-over-year growth rate of 64.2%. The company is expected to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that bluebird bio will report full year earnings of ($4.97) per share for the current financial year, with EPS estimates ranging from ($6.57) to ($4.11). For the next financial year, analysts expect that the business will post earnings of ($2.92) per share, with EPS estimates ranging from ($4.37) to ($1.80). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that cover bluebird bio.

bluebird bio (NASDAQ:BLUEGet Rating) last issued its quarterly earnings results on Monday, May 9th. The biotechnology company reported ($1.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.10). The company had revenue of $1.95 million during the quarter, compared to analyst estimates of $0.17 million. bluebird bio had a negative return on equity of 111.73% and a negative net margin of 2,183.15%. The company’s revenue was up 117.6% on a year-over-year basis. During the same period in the prior year, the company posted ($3.07) earnings per share.

Several analysts recently commented on the stock. Wedbush cut their target price on shares of bluebird bio from $10.00 to $8.00 and set a “neutral” rating for the company in a research note on Tuesday, May 10th. SVB Leerink cut their target price on shares of bluebird bio from $10.00 to $8.00 and set a “market perform” rating for the company in a research note on Wednesday, April 6th. Cowen lowered shares of bluebird bio from an “outperform” rating to a “market perform” rating in a research note on Wednesday, April 6th. Wells Fargo & Company cut their target price on shares of bluebird bio from $12.00 to $8.00 and set an “equal weight” rating for the company in a research note on Tuesday, March 8th. Finally, Morgan Stanley cut their target price on shares of bluebird bio to $3.00 and set an “underweight” rating for the company in a research note on Tuesday, May 17th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $12.00.

A number of institutional investors have recently added to or reduced their stakes in BLUE. Morgan Stanley increased its stake in bluebird bio by 70.7% in the 2nd quarter. Morgan Stanley now owns 684,780 shares of the biotechnology company’s stock valued at $21,899,000 after buying an additional 283,517 shares during the period. Deutsche Bank AG increased its stake in shares of bluebird bio by 81.1% during the 3rd quarter. Deutsche Bank AG now owns 104,740 shares of the biotechnology company’s stock worth $2,002,000 after purchasing an additional 46,910 shares during the last quarter. Advisor Group Holdings Inc. increased its stake in shares of bluebird bio by 18.4% during the 3rd quarter. Advisor Group Holdings Inc. now owns 14,515 shares of the biotechnology company’s stock worth $277,000 after purchasing an additional 2,259 shares during the last quarter. Swiss National Bank increased its stake in shares of bluebird bio by 0.7% during the 3rd quarter. Swiss National Bank now owns 149,107 shares of the biotechnology company’s stock worth $2,849,000 after purchasing an additional 1,100 shares during the last quarter. Finally, Principal Financial Group Inc. increased its stake in shares of bluebird bio by 3.2% during the 3rd quarter. Principal Financial Group Inc. now owns 442,564 shares of the biotechnology company’s stock worth $8,457,000 after purchasing an additional 13,630 shares during the last quarter. Hedge funds and other institutional investors own 96.38% of the company’s stock.

BLUE stock traded up $0.12 on Friday, hitting $3.28. 2,301,302 shares of the company’s stock traded hands, compared to its average volume of 2,314,418. bluebird bio has a 1-year low of $2.89 and a 1-year high of $35.59. The stock has a market cap of $234.37 million, a price-to-earnings ratio of -0.31 and a beta of 1.63. The stock has a fifty day moving average of $4.14 and a 200-day moving average of $6.88.

bluebird bio Company Profile (Get Rating)

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy.

Featured Articles

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.